Editas Medicine, Inc. (EDIT)
2.90
+0.06
(+2.11%)
USD |
NASDAQ |
Oct 09, 16:00
2.87
-0.03
(-1.03%)
After-Hours: 20:00
Editas Medicine Cash from Operations (Quarterly) : -29.57M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -29.57M |
| March 31, 2026 | -23.06M |
| December 31, 2025 | -36.39M |
| September 30, 2025 | -30.84M |
| June 30, 2025 | -50.21M |
| March 31, 2025 | -47.80M |
| December 31, 2024 | -50.76M |
| September 30, 2024 | -52.59M |
| June 30, 2024 | -57.06M |
| March 31, 2024 | -49.87M |
| December 31, 2023 | -22.24M |
| September 30, 2023 | -35.46M |
| June 30, 2023 | -38.71M |
| March 31, 2023 | -35.77M |
| December 31, 2022 | -42.27M |
| September 30, 2022 | -48.00M |
| June 30, 2022 | -37.84M |
| March 31, 2022 | -49.23M |
| December 31, 2021 | -34.58M |
| September 30, 2021 | -40.78M |
| June 30, 2021 | -38.96M |
| March 31, 2021 | -49.48M |
| December 31, 2020 | -40.10M |
| Date | Value |
|---|---|
| September 30, 2020 | -54.80M |
| June 30, 2020 | -30.86M |
| March 31, 2020 | -54.09M |
| December 31, 2019 | 41.02M |
| September 30, 2019 | -26.88M |
| June 30, 2019 | -25.81M |
| March 31, 2019 | -29.00M |
| December 31, 2018 | 1.327M |
| September 30, 2018 | -7.841M |
| June 30, 2018 | -16.73M |
| March 31, 2018 | -22.46M |
| December 31, 2017 | -25.07M |
| September 30, 2017 | -27.98M |
| June 30, 2017 | -26.16M |
| March 31, 2017 | 69.79M |
| December 31, 2016 | -13.36M |
| September 30, 2016 | -17.04M |
| June 30, 2016 | -9.899M |
| March 31, 2016 | -9.629M |
| December 31, 2015 | -7.968M |
| September 30, 2015 | -11.94M |
| June 30, 2015 | 20.45M |
| March 31, 2015 | -5.943M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Recursion Pharmaceuticals, Inc. | -105.95M |
| Geron Corp. | -15.83M |
| Halozyme Therapeutics, Inc. | 240.89M |
| Novavax, Inc. | -72.81M |
| AVITA Medical, Inc. | -3.630M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -29.80M |
| Cash from Financing (Quarterly) | 117.54M |
| Free Cash Flow | -120.55M |
| Free Cash Flow Per Share (Quarterly) | -0.2487 |
| Free Cash Flow to Equity (Quarterly) | -28.95M |
| Free Cash Flow to Firm (Quarterly) | -28.61M |
| Free Cash Flow Yield | -41.10% |